MOSCOW, Sep 4 (PRIME) -- Publication in magazine The Lancet summarizing two rounds of clinical trials of Russian vaccine for the coronavirus Sputnik V has proven its safety and effectiveness, CEO Russian Direct Investment Fund (RDIF) CEO Kirill Dmitriev said on Friday, as cited in a statement.
"Publication in one of the world’s most respected medical magazines, The Lancet, proves high safety and effectiveness of the Russian vaccine Sputnik V and demonstrates recognition of Russian scientists by the global scientific community," Dmitriev said.
He said that the results of post registration study will be released in October–November. Clinical trials in Saudi Arabia and the Philippines are scheduled for September.
Dmitriev said that the RDIF will announce the first export deals next week.
"We will start to disclose the sales agreements for the Russian vaccine to the foreign markets next week. There will be many reports about various partnerships with the countries that are ready to buy the Russian vaccine," the CEO said.
The Healthcare Ministry registered the world’s first coronavirus vaccine on August 11. At first, the Gamaleya institute and pharmaceutical company Binnopharm will produce the vaccine, and R-Pharm and Generium will soon join them. Multi-industry holding Sistema said that Binnopharm’s capacities allow it to produce 1.5 million doses of the vaccine per year, and that it planned to start mass production until the end of 2020.
End %%mk/jst%%
|
|
